KSQ Boosts PARP Inhibition In Models Of Cancer With USP1 Inhibitor
KSQ Therapeutics is hoping to provide hope for ovarian and breast cancer patients that have developed a resistance to drugs and those who don’t respond at all by developing a drug that may be able to boost the effectiveness of PARP inhibitors such as Lynparza when used in combination with it, and the company has …